Viral Hepatitis Other than A, B, and C

Cheung, Amanda; Kwo, Paul Y.

doi:10.1016/j.cld.2020.04.008

Cited by 12 publications

(15 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Liver biopsy is still of election to achieve an accurate inflammation grading and fibrosis staging since fibrosis noninvasive markers are not reliable in chronic HDV infection. The higher inflammation in HDV compared to HBV monoinfection alters elastography measurement, so the accuracy of transient elastography seems to be reasonable to detect cirrhosis but remains to be validated for grading lesser degrees of fibrosis[ 1 , 166 - 168 ].…”

Section: Hcvmentioning

confidence: 99%

“…Nucleoside/NAs are ineffective because they do not reduce HBsAg levels, which is required for HDV propagation. However, despite the presence of HDV typically suppressing HBV replication, nucleoside/NA (entecavir or tenofovir) is generally recommended, particularly in patients with cirrhosis, regardless of HBV replication status[ 1 ]. Nevertheless, the Hep-Net International Delta Hepatitis Intervention Trial, a large multicenter program, treated patients with PEG-IFN-a-2a and/or adefovir for 48 wk.…”

Section: Hcvmentioning

confidence: 99%

“…As of today, five viruses (hepatitis A, B, C, D, and E) that selectively infect the liver, usually by different routes, have been recognized. In some of these viral infections, acute hepatitis can resolved without intervention, whereas, sometimes, the process turns into a chronic infection[ 1 ]. Huge medical advances made in recent decades led to the implementation of preventive measures, the development of vaccines and passive immunization strategies, and, more recently, the development of promising and effective treatments, at least for some forms of viral hepatitis.…”

Section: Introductionmentioning

confidence: 99%

“…The results obtained by basic research on viruses and on viruses-cell interaction made it possible to struggle with what a century ago seemed an insurmountable scourge on humanity. Achievements in hepatitis prevention and treatment are perhaps the paradigm of successful translational research[ 1 ]. Nonetheless, viral hepatitis is still a global public health concern that affects millions of people and causes thousands of deaths due to acute and chronic infection, cirrhosis, and liver cancer[ 1 , 2 ].…”

Section: Introductionmentioning

confidence: 99%

“…Achievements in hepatitis prevention and treatment are perhaps the paradigm of successful translational research[ 1 ]. Nonetheless, viral hepatitis is still a global public health concern that affects millions of people and causes thousands of deaths due to acute and chronic infection, cirrhosis, and liver cancer[ 1 , 2 ]. This review focuses on the currently most important research topics and future research directions that can maximize practical impact in the field of viral hepatitis.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Viral hepatitis update: Progress and perspectives

Pisano¹,

Giadans²,

Flichman³

et al. 2021

WJG

View full text Add to dashboard Cite

Viral hepatitis, secondary to infection with hepatitis A, B, C, D, and E viruses, are a major public health problem and an important cause of morbidity and mortality. Despite the huge medical advances achieved in recent years, there are still points of conflict concerning the pathogenesis, immune response, development of new and more effective vaccines, therapies, and treatment. This review focuses on the most important research topics that deal with issues that are currently being solved, those that remain to be solved, and future research directions. For hepatitis A virus we will address epidemiology, molecular surveillance, new susceptible populations as well as environmental and food detections. In the case of hepatitis B virus, we will discuss host factors related to disease, diagnosis, therapy, and vaccine improvement. On hepatitis C virus, we will focus on pathogenesis, immune response, direct action antivirals treatment in the context of solid organ transplantation, issues related to hepatocellular carcinoma development, direct action antivirals resistance due to selection of resistance-associated variants, and vaccination. Regarding hepatitis D virus, we describe diagnostic methodology, pathogenesis, and therapy. Finally, for hepatitis E virus, we will address epidemiology (including new emerging species), diagnosis, clinical aspects, treatment, the development of a vaccine, and environmental surveillance.

show abstract

Section: Hcvmentioning

confidence: 99%

Section: Hcvmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%